Pfizer logo

Pfizer

PFIZER NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹17,628 Cr
Volatility
Low Risk
P/E Ratio
24.01
EBITDA
₹1,092 Cr
Return on Equity
17.19%
Debt to Equity
0.02
Book Value
₹918.71
EPS
₹131.73
52W High
₹5,578.5
52W Low
₹3,833.5

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 58.3%

Weaknesses

1
  • The company has delivered a poor sales growth of 2.39% over past five years.

Growth Rate

Revenue Growth
10.35% higher than 3Y
Net Income Growth
-5.89% lower than 3Y
Cash Flow Change
46.66% lower than 3Y
ROE
-5.55% lower than 3Y
ROCE
-2.8% lower than 3Y
EBITDA Margin (Avg.)
8.44% lower than 3Y

AI Analysis — Bull vs Bear

6d ago
AI opinion · based on fundamentals
Risk medium

Pfizer Ltd is a ₹18,312 crore healthcare company. It trades at a P/E of 25.2x and a P/B of 4.41x, is almost debt free and has a dividend yield of 1.85%. Profit has grown faster than sales: 10-year profit CAGR is 10% against 2% for sales, and TTM sales grew 11% after years of low single-digit growth. The stock has returned -19% over 1 year and -7% CAGR over 5 years, while ROE has stayed steady at 16-18%.

Bull Case 7
  • TTM sales growth of 11% is well above the 3-year sales CAGR of 1% and the 5-year CAGR of 2%, which may point to recovering revenue momentum.
  • TTM profit growth of 14% continues a record of profit growing faster than sales: 10-year profit CAGR is 10% against 2% for sales, suggesting margin expansion and cost discipline.
  • ROE has stayed steady at 16-18% over 3, 5 and 10 years (last year 18%, 10-year 17%), showing consistent capital efficiency.
  • The company is almost debt free and has reduced debt further, which lowers financial risk and interest costs for a ₹18,312 crore business.
  • A healthy dividend payout of 58.3% supports a dividend yield of 1.85%, a steady cash return to shareholders.
  • A P/E of 25.2x is moderate for Indian pharma MNCs, which often trade at higher multiples, especially given 14% TTM profit growth.
  • After a -19% 1-year stock return, the valuation has compressed while TTM profit grew 14%, narrowing the gap between price and fundamentals.
Bear Case 8
  • Five-year sales CAGR is only 2.39% and the 10-year sales CAGR is 2%, both likely below nominal GDP and pharma market growth, pointing to weak top-line expansion.
  • Three-year sales CAGR of just 1% raises doubts about whether 11% TTM sales growth can last or is a one-off rebound.
  • The stock has returned -19% over 1 year and -7% CAGR over 5 years, destroying shareholder value over the medium term despite profit growth.
  • A 3-year stock CAGR of 1% means shareholders have seen almost no price appreciation, even with a 3-year profit CAGR of 8%.
  • A P/B of 4.41x is a significant premium to book value for a company with about 2% long-term sales growth, which limits room for re-rating.
  • Profit growth (10-year CAGR of 10%) has leaned heavily on margin gains rather than volume, and margins cannot expand forever if sales keep growing at around 2%.
  • The 3-year ROE of 16% is lower than the 5-year ROE of 18%, a slight softening in capital efficiency over the recent period.
  • A 58.3% dividend payout leaves limited retained earnings for reinvestment. This may be one reason sales growth has been limited to 2% over 5 and 10 years.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago
Headwinds 1
  • ₹1.26 crore transfer pricing penalty Sep 29

    Pfizer Limited received a ₹1.26 crore penalty from the Income Tax Transfer Pricing authority for AY 2023-24. The company plans to appeal and says there is no material impact on its financials.

Positives 1
  • $13.9M Minipress XL payout Sep 7

    Pfizer Limited will receive a lump sum of $13.9 million (~₹131.38 crore), approved by the Board on September 7, 2026, after discontinuing Minipress XL sales effective the same day. The one-time cash gain comes with the loss of future revenue from the product, which follows Pfizer Inc. USA halting manufacture.

Neutral 1
  • Policy head Sharad Goswami resigns Sep 18

    Sharad Goswami, Senior Director – Policy & Public Affairs, resigned to pursue external opportunities. He ceases to be Senior Management Personnel effective September 25, 2026.

TL;DR: Recent news for Pfizer Ltd is mostly low-impact. The largest item is a one-time ₹131.38 crore payment for discontinuing Minipress XL, which helps near-term earnings but removes a product from the portfolio. The ₹1.26 crore tax penalty and a senior policy executive leaving are not material to financials. The trend is stable rather than improving or worsening, so watch whether Pfizer replaces the lost Minipress XL revenue and how the AY 2023-24 tax appeal turns out.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
531
575
540
547
563
589
538
592
603
642
645
629
653
Expenses
421
393
387
357
385
399
392
364
393
412
417
393
406
Operating Profit
111
183
153
189
177
189
146
228
210
230
228
236
248
OPM %
21%
32%
28%
35%
32%
32%
27%
38%
35%
36%
35%
38%
38%
Other Income
33
36
44
75
42
43
43
217
67
42
-20
50
45
Interest
3
3
3
7
2
2
2
3
3
2
2
2
1
Depreciation
16
15
18
14
15
15
15
16
14
14
14
15
14
PBT
126
201
176
244
203
215
172
426
260
255
192
269
277
Tax %
26%
26%
26%
27%
26%
26%
26%
22%
26%
26%
26%
26%
26%
Net Profit
94
149
130
179
151
158
128
331
192
189
142
200
204
EPS in Rs
20.44
32.56
28.41
39.1
32.94
34.61
27.89
72.34
41.91
41.32
31
43.68
44.7
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,853
2,012
1,966
1,969
2,082
2,152
2,239
2,611
2,425
2,193
2,281
2,520
2,570
Expenses
1,438
1,579
1,616
1,468
1,516
1,578
1,526
1,775
1,616
1,555
1,540
1,615
1,628
Operating Profit
414
433
350
501
566
574
712
836
809
638
742
904
942
OPM %
22%
22%
18%
25%
27%
27%
32%
32%
33%
29%
33%
36%
37%
Other Income
44
97
232
114
167
183
81
63
134
185
344
139
116
Interest
2
1
2
1
2
11
15
11
13
15
8
10
8
Depreciation
250
58
63
66
71
103
109
115
106
62
61
58
58
PBT
207
470
517
548
660
642
669
773
824
746
1,016
976
993
Tax %
66%
35%
35%
34%
35%
21%
26%
21%
24%
26%
24%
26%
—
Net Profit
70
305
337
360
429
509
498
613
624
551
768
722
735
EPS in Rs
15.26
66.67
73.62
78.71
93.79
111
109
134
136
121
168
158
161
Div. Payout %
82%
22%
27%
25%
24%
297%
32%
26%
29%
29%
98%
48%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
46
46
46
46
46
46
46
46
46
46
46
46
Reserves
1,927
2,118
2,373
2,637
2,966
3,350
2,347
2,819
3,162
3,550
4,172
4,157
Borrowings
2
2
2
2
2
2
63
39
41
40
108
70
Other Liabilities
638
722
840
1,004
926
1,007
810
997
752
593
585
649
Total Liabilities
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
Fixed Assets
944
925
902
950
886
973
894
869
749
713
724
678
CWIP
13
3
15
1
0
1
3
1
8
0
8
20
Investments
43
37
0
0
0
0
0
0
0
0
0
0
Other Assets
1,614
1,923
2,343
2,739
3,054
3,432
2,369
3,030
3,244
3,516
4,180
4,224
Total Assets
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
113
345
329
332
98
323
427
667
356
257
660
968
Investing
68
-701
-250
-238
35
1,530
-469
-575
-36
54
-71
-562
Financing
-1
-62
-83
-110
-110
-164
-1,571
-181
-346
-235
-205
-798
Net Cash Flow
181
-417
-3
-17
23
1,690
-1,613
-88
-26
75
383
-392
Free Cash Flow
93
398
394
262
125
343
410
654
292
291
783
944
CFO/OP
62
120
146
105
59
93
89
107
81
64
110
105
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
32
26
20
29
30
29
18
20
23
31
31
26
Inventory Days
191
167
148
147
189
198
199
173
175
200
214
195
Days Payable
165
157
178
245
213
197
130
102
91
77
68
89
Cash Conversion Cycle
58
36
-10
-69
6
31
87
91
107
154
177
132
Working Capital Days
7
-9
-47
-57
-16
-8
3
-14
1
24
23
9
ROCE %
24%
22%
17%
21%
23%
20%
23%
29%
26%
22%
21%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Pfizer insights

65 extracted metrics + investor summaries across FY06–FY27.

Log in — free

Shareholding Pattern

FIIs1.65%Promot.63.92%Others4.59%Public12.04%DIIs17.80%As ofJun 2026

Documents

Frequently Asked Questions about Pfizer

What does Pfizer Ltd do?
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors...
Where is Pfizer Ltd (PFIZER) listed?
Pfizer Ltd trades as PFIZER on the NSE and under code 500680 on the BSE.
Which sector does Pfizer Ltd belong to?
Pfizer Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Pfizer Ltd?
Pfizer Ltd has a market capitalisation of ₹17,628 Cr, which places it in the Mid Cap band.
What is the PE ratio of Pfizer Ltd?
Pfizer Ltd trades at a PE ratio of 24.01, on earnings per share of ₹131.73, against a book value of ₹918.71 per share.
What is the 52-week high and low of Pfizer Ltd?
Over the last 52 weeks Pfizer Ltd has traded between ₹3,833.5 and ₹5,578.5.
Does Pfizer Ltd pay dividends?
Pfizer Ltd has a dividend yield of 1.94%.
What is the Return on Equity (ROE) of Pfizer Ltd?
Pfizer Ltd reported a return on equity of 17.19%. Its debt-to-equity ratio is 0.02.

Company Information

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1] It is the 3rd largest multinational pharmaceutical company in India.[2]

Website pfizerindia.com
CEO Ms. Meenakshi Nevatia
Employees 1,598
Listed 1999-04-28
Face Value ₹ 10
Issued Size 4,57,47,732

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PFIZER.md for Pfizer Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List